(BW) BIO-FLUORESCENT-TECH)(BFTI) BFTI receives Peruvian naval approval to conduct trials for its rapid immunochromatographic assay for detection of the HIV 1/2 viruses

(BW) BIO-FLUORESCENT-TECH)(BFTI) BFTI receives Peruvian naval approval to conduct trials for its rapid immunochromatographic assay for detection of the HIV 1/2 viruses

BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - BW1028 DEC 28,1995 6:00 PACIFIC 09:00 EASTERN

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Dec. 28, 1995-- Bio-Fluorescent Technologies Inc. (OTC BB:BFTI) Thursday announced it had received approval from the Peruvian Ministry of Interior, which is in charge of the armed forces and police, to conduct trials with the navy.

Tests will be conducted on 100 individuals using BFTI's rapid assay test for the HIV 1/2 virus. These trials are the first step required by the navy department to qualify a product for purchase. The navy department plans on making HIV tests available for all naval personnel and their families. This specific Peruvian market could provide BFTI with sales up to $4 million in 1996.

Bio-Fluorescent Technologies Inc. is an international marketing company specializing in leading edge human screening and confirmatory immuno assays including HIV. The company's flagship product known as the MEHICA GP120 combines leading edge satellite imaging technology with state-of-the-art bio-chemistry.

The MEHICA GP120 provides the only mechanized equipment available today to quickly and accurately process immuno-fluorescent assay (IFA) tests.

--30--li/ix*

CONTACT: Bio Fluorescent Technologies Inc., Scottsdale George, 800/870-1233 or Margaret, 800/665-1335

KEYWORD: ARIZONA INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY

REPEATS: New York 212-575-8822 or 800-221-2462; Boston 617-236-4266 or 800-225-2030; SF 415-986-4422 or 800-227-0845; LA 310-820-9473 BW URL: http://www.hnt.com/bizwire

Copyright (c) 1995/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.

951228
BW951211

Copyright © 1995 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .